Genmab A (GMAB) Non-Current Deferred Tax Liability (2024 - 2026)

Genmab A (GMAB) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $364.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Deferred Tax Liability rose 10.3% year-over-year to $364.0 million; the trailing twelve-month figure through Jun 2026 stood at $364.0 million (up 10.3% YoY), and the FY2025 full-year result was $364.0 million, up 10.3% from the prior year.
• Non-Current Deferred Tax Liability steadied at $364.0 million in Q2 2026 per GMAB's latest filing, from $365.0 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $365.0 million in Q1 2026 and bottomed at $169.2 million in Q3 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $293.9 million across 3 years, with a median of $330.0 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deferred Tax Liability surged 95.09% in 2025, then rose 10.3% in 2026.
• Over 3 years, Non-Current Deferred Tax Liability stood at $219.5 million in 2024, then soared by 65.84% to $364.0 million in 2025, then changed by 0.0% to $364.0 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $364.0 million, $365.0 million, and $364.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.